Wegovy HD 7.2mg: The New Higher-Dose Weight Loss Injection in One Weekly Pen

The introduction of the Wegovy HD 7.2mg single-dose pen marks an important advancement in obesity treatment. Designed to deliver a higher dose of semaglutide in one convenient weekly injection, Wegovy HD provides healthcare professionals with an additional treatment option for patients requiring greater weight loss support than the standard 2.4mg maintenance dose.

Backed by data from the Phase IIIb STEP UP clinical trial, Wegovy HD 7.2mg demonstrated impressive weight loss outcomes while maintaining a safety profile consistent with lower-dose semaglutide treatment. The availability of a dedicated single-dose pen also offers a more convenient treatment experience, allowing patients to receive their full weekly dose in one injection.

What Is Wegovy HD 7.2mg?

Wegovy HD 7.2mg is a higher-dose version of semaglutide, a GLP-1 receptor agonist used for chronic weight management in adults living with obesity or weight-related health conditions.

Like standard Wegovy, Wegovy HD works by:

• Reducing appetite
• Increasing feelings of fullness
• Helping patients consume fewer calories
• Supporting long-term weight management

The higher 7.2mg dose has been developed for patients who may benefit from additional weight loss beyond what is typically achieved with the standard 2.4mg maintenance dose.

STEP UP Clinical Trial Results

The Phase IIIb STEP UP trial evaluated the efficacy and safety of semaglutide 7.2mg in adults with obesity who did not have type 2 diabetes.

The study followed more than 1,400 participants over a 72-week treatment period and compared outcomes between the higher 7.2mg dose, the standard 2.4mg dose and placebo.

Key Findings

The results demonstrated that Wegovy HD 7.2mg delivered significant weight loss:

• Average weight loss of approximately 20.7% after 72 weeks
• Greater average weight loss compared with the standard 2.4mg dose
• More than one-third of participants lost at least 25% of their starting body weight
• More than 90% of participants achieved at least 5% weight loss

These findings suggest that higher-dose semaglutide may offer an effective option for patients who require additional support to achieve meaningful weight reduction.

Wegovy HD 7.2mg Single-Dose Pen

One of the key advantages of Wegovy HD is the availability of a dedicated single-dose pen.

The pen delivers the full 7.2mg weekly dose in one injection, simplifying treatment and reducing administration complexity.

Benefits of the Single-Dose Pen

• One injection per week
• Convenient administration
• Reduced treatment burden
• Simplified dosing
• Potentially improved adherence
• Familiar Wegovy injection experience

For patients progressing to higher-dose semaglutide therapy, the single-dose device offers a straightforward and convenient treatment option.

How Effective Is Wegovy HD 7.2mg?

Clinical evidence indicates that Wegovy HD can help patients achieve substantial weight loss when used alongside dietary, physical activity and lifestyle interventions.

Many patients who respond well to semaglutide treatment may benefit from the increased dose, particularly if they have not yet reached their weight management goals on lower doses.

As with all weight loss medications, individual results will vary and treatment suitability should be assessed by a qualified healthcare professional.

Is Wegovy HD 7.2mg Safe?

The safety profile observed in clinical studies was consistent with previously established semaglutide data.

The most commonly reported side effects included:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort

These side effects were generally mild to moderate and most commonly occurred during dose escalation.

Patients should always follow medical guidance and report any concerns to their healthcare provider.

Who May Benefit from Wegovy HD 7.2mg?

Wegovy HD may be suitable for:

• Adults living with obesity
• Patients requiring additional weight loss support
• Individuals who have successfully tolerated lower doses of semaglutide
• Patients working towards significant long-term weight reduction goals

Treatment decisions should always be made in consultation with a qualified prescriber.

Wegovy HD 7.2mg vs Standard Wegovy 2.4mg

While both treatments contain semaglutide and are administered once weekly, Wegovy HD provides a higher maintenance dose designed to deliver greater weight loss outcomes for appropriate patients.

Clinical trial data demonstrated higher average weight loss with the 7.2mg dose compared with the standard 2.4mg maintenance dose, expanding the range of treatment options available for obesity management.

The Future of Medical Weight Loss

The arrival of Wegovy HD 7.2mg reflects the continued evolution of evidence-based obesity treatment.

With clinical trial data demonstrating average weight loss exceeding 20%, and the convenience of a dedicated single-dose pen, Wegovy HD provides an additional option for patients seeking clinically proven weight management support.

As understanding of obesity as a chronic medical condition continues to grow, treatments such as Wegovy HD are helping to expand the range of personalised options available to patients and healthcare professionals.

Frequently Asked Questions

What is Wegovy HD 7.2mg?

Wegovy HD 7.2mg is a higher-dose semaglutide weight loss treatment delivered via a convenient single-dose weekly injection pen.

Is Wegovy HD 7.2mg available as a single-dose pen?

Yes. Wegovy HD 7.2mg is available as a dedicated single-dose pen, allowing patients to receive the full weekly dose in one injection.

How much weight can patients lose with Wegovy HD 7.2mg?

In the STEP UP trial, participants achieved average weight loss of approximately 20.7% after 72 weeks, with more than one-third losing at least 25% of their starting body weight.

What are the common side effects of Wegovy HD?

The most commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort.

Who is Wegovy HD suitable for?

Wegovy HD may be considered for adults living with obesity who require additional weight loss support and have successfully tolerated lower semaglutide doses under medical supervision.

Conclusion

Wegovy HD 7.2mg represents a significant advancement in medical weight management. Supported by robust clinical evidence and delivered through a convenient single-dose pen, it offers an additional treatment option for patients seeking greater weight loss outcomes under professional medical guidance.

Patients interested in Wegovy HD should complete a Pharmulous online assessment to determine whether the treatment is appropriate for their individual circumstances.

References

1. Rubino D, Garvey WT, et al. *Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, double-blind, phase 3 trial.* The Lancet Diabetes & Endocrinology. 2025. Available at: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00226-8/abstract

2. Novo Nordisk. *CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss.* 2025. Available at: https://uk.finance.yahoo.com/news/novo-nordisk-chmp-recommends-eu-173000328.html

3. Garvey WT, et al. *Efficacy and Safety of Semaglutide 7.2 mg in Obesity — STEP UP Trial.* Diabetes. 2025;74(Supplement 1):1966-LB. Available at: https://diabetesjournals.org/diabetes/article/74/Supplement_1/1966-LB/158768/1966-LB-Efficacy-and-Safety-of-Semaglutide-7-2-mg

4. Applied Clinical Trials. *STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss Versus Semaglutide 2.4 mg and Placebo.* January 2025. Available at: https://www.appliedclinicaltrialsonline.com/view/step-up-trial-semaglutide-superior-weight-loss

5. HCP Live. *Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial.* January 2025. Available at: https://www.hcplive.com/view/semaglutide-7-2-mg-displays-20-7-weight-loss-in-phase-3b-step-up-trial

6. Pharmacy Times. *Investigational Dose of Semaglutide Shows 20.7% Weight Loss at 72 Weeks.* January 2025. Available at: https://www.pharmacytimes.com/view/investigational-dose-of-semaglutide-shows-20-7-weight-loss-at-72-weeks

7. Novo Nordisk Canada. *Higher dose of semaglutide provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA.* 2025. Available at: https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/2025/step-up-nnci-press-release-english.pdf

8. BioSpace. *Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence.* January 2025. Available at: https://www.biospace.com/press-releases/novo-nordisk-a-s-semaglutide-7-2-mg-s-c-achieved-20-7-weight-loss-in-the-step-up-obesity-trial-and-18-7-regardless-of-treatment-adherence